Last reviewed 2026-04-20 · How we verify

Diovan

Diovan, marketed by Bayer, is a leading treatment for chronic heart failure. Its key strength lies in its well-established mechanism and market presence, supported by a key composition patent expiring in 2028. The primary risk is the eventual loss of exclusivity post-patent expiry, which could lead to increased competition from generics.

At a glance

Approved indications

• Chronic heart failure
• Hypertensive disorder
• Left ventricular cardiac dysfunction

Common side effects

• Nasopharyngitis
• Dizziness
• Headache
• Dry cough

Serious adverse events

• Hypotension
• Orthostatic effects
• Angioedema

Key clinical trials

• Efficacy and Safety of Sacubitril/Valsartan in African American Patients With Heart Failure With Reduced Ejection Fraction
• Manganese-enhanced Magnetic Resonance Imaging in Takotsubo Cardiomyopathy (NA)
• Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3 (PHASE4)
• Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan (PHASE1, PHASE2)
• A Real-world Study of Clinical Treatment Guidelines for Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan
• A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction (PHASE1)
• A Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive Patients in the United Arab Emirates
• The ENCHANTMENT HIV Study (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Diovan CI brief — competitive landscape report
• Diovan updates RSS · CI watch RSS
• Bayer portfolio CI